Somatic mutations in cancer cells can generate tumour-specific neoepitopes, which are
recognized by autologous T cells in the host. As neoepitopes are not subject to central …

Most (if not all) tumors emerge and progress under a strong evolutionary pressure imposed
by trophic, metabolic, immunological, and therapeutic factors. The relative impact of these …

Liver metastasis, the leading cause of colorectal cancer mortality, exhibits a highly
heterogeneous and suppressive immune microenvironment. Here, we sequenced 97 …

Abstract 'Immune checkpoint blockade'for cancer describes the use of therapeutic antibodies
that disrupt negative immune regulatory checkpoints and unleash pre-existing antitumour …

Knowledge of immune cell phenotypes in the tumor microenvironment is essential for
understanding mechanisms of cancer progression and immunotherapy response. We …

Metastatic progression is the main cause of death in cancer patients, whereas the
underlying genomic mechanisms driving metastasis remain largely unknown. Here, we …

Efforts to develop anti-cancer therapies have largely focused on targeting the epithelial
compartment, despite the presence of non-neoplastic stromal components that substantially …

Advances in our understanding of molecular mechanisms of tumorigenesis have translated
into knowledge-based therapies directed against specific oncogenic signaling targets …

New therapies that promote antitumour immunity have been recently developed. Most of
these immunomodulatory approaches have focused on enhancing T-cell responses, either …

Cancer immunoediting is a hallmark of cancer that predicts that lymphocytes kill more
immunogenic cancer cells to cause less immunogenic clones to dominate a population …